Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$6.45 USD
+0.27 (4.37%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $6.47 +0.02 (0.31%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Income Statements
Fiscal Year end for Mind Medicine MindMed Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 94 | 66 | 94 | 33 | 11 |
Income After Depreciation & Amortization | -94 | -66 | -94 | -33 | -11 |
Non-Operating Income | -2 | 10 | 0 | -1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -96 | -57 | -94 | -34 | -11 |
Income Taxes | 0 | 0 | -1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -96 | -57 | -93 | -34 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -96 | -57 | -93 | -34 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -91 | -63 | -91 | -33 | -11 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 3 | 0 | 0 |
Income After Depreciation & Amortization | -94 | -66 | -94 | -33 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 39.16 | 30.86 | 27.39 | 24.09 | NA |
Diluted EPS Before Non-Recurring Items | -2.44 | -2.09 | -3.45 | -1.50 | NA |
Diluted Net EPS (GAAP) | -2.44 | -1.84 | -3.45 | -1.50 | NA |
Fiscal Year end for Mind Medicine MindMed Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 24.46 | 22.21 | 22.21 | 21.61 | 29.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | -24.46 | -22.21 | -22.21 | -21.61 | -29.19 |
Non-Operating Income | 19.07 | -31.76 | -1.66 | 3.69 | 0.05 |
Interest Expense | 0.47 | 0.43 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.85 | -54.40 | -23.86 | -17.92 | -29.13 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.85 | -54.40 | -23.86 | -17.92 | -29.13 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.85 | -54.40 | -23.86 | -17.92 | -29.13 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 75.30 | 47.86 | 40.45 | 39.72 | 38.58 |
Diluted EPS Before Non-Recurring Items | -0.48 | -0.60 | -0.59 | -0.53 | -0.72 |
Diluted Net EPS (GAAP) | -0.26 | -1.14 | -0.58 | -0.45 | -0.76 |